Address: Insure Insights 61 Bridge Street, Kington.HR5 3DJ United Kingdom

Global Antidiabetics Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Home
  • Reports
  • Global Antidiabetics Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028
Global Antidiabetics Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

Global Antidiabetics Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Published Date: 17 May 2021
  • Report ID: HLT 00208
  • Pages:174
  • Base Year: 2019
  • Format: PDF
  • Historical Data: 2016-2019

Market Forecast, 2019-2028

Global Antidiabetics Market is anticipated to rise at a value CAGR of 10.35% over 2019-2028. According to a study published by Insure Insights on the Global Antidiabetics Market. Antidiabetics are those drugs used in the treatment of Diabetes; they include insulins and drugs, they are used to stabilize and control blood glucose levels in people with Diabetes. The American Diabetes Association has reported that in the year 2018, about 34.2 million Americans, i.e., about 10.5% of the population, had Diabetes, and 1.5 million Americans are diagnosed with Diabetes every year. The increase in R&D spending by pharmaceutical companies for drug development are driving the demand and adoption of antidiabetic drugs

Top Driver: The rise in the incidences of Diabetes around the globe have escalated the demand of the market

The surge in population growth and the rise in the geriatric population have increased the market growth owing rise in the incidence of diabetes worldwide. The rise in the prevalence of lifestyle-induced disorders like obesity has escalated market revenue. The Advancement in antidiabetic drugs and the Need for effective treatment with low side effects have improved the demand for Antidiabetic drugs.

Insulin in the product segment has made the highest segmental growth in the Global Antidiabetics Market

Based on the Product, Insulin segment has dominated the segmental growth due to the wide variety of Insulin available to control the glucose level of the body. The introduction of short-acting Insulin has gained more importance as it is helpful in post-prandial glucose-controlling ability in both type 1 and type 2 diabetic patients. The development of new Insulin products has increased the preference of Insulin over drugs by the healthcare professionals and thus have expanded the market growth.

In terms of the Patient Population, the Geriatric population segment has obtained the most significant growth as Type 2 diabetes is more prevalent in elderly people; the growth in the geriatric population around the globe has further expanded the market.  Based on the Route of administration, Subcutaneous Route segment has obtained the most remarkable growth owing to the rise in the demand for Insulin.

North America boosts the regional market due to an increase in the population growth   

North America had held the highest growth in the region due to the high demand for modern insulin products such as long-acting, rapid-acting insulin analog. The rise in the geriatric population suffering from diabetes and advances in healthcare infrastructure has boosted the regional market revenue. The growth in the healthcare expenditure growing prevalence of the people with type I and type II diabetes have escalated the regional growth. The rise in government initiatives in diabetes management has further escalated regional growth.

 Product Launches, new advances Strategic Collaborations, Mergers, and Acquisition, are the major strategies of the competitors

The Players of the Global Antidiabetics Market is fragmented.  Product launches, new advances collaborations, mergers, and acquisitions are strategies used by competitors. The key competitors of the Global Antidiabetics Market are Astra Zeneca plc, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim GmbH and Teva Pharmaceutical Industries Ltd.

Astra Zeneca plc: Astra Zeneca plc, is one of the key competitors of the Global Antidiabetics Market; for instance, In February 2020, Astra Zeneca had announced the launch of Qtern tablets, For the treatment of type 2 diabetes for India. Qtern tablets consist of Dapagliflozin 10mg, Saxagliptin 5mg; it is a film-coated tablet. It is used to improve the glycaemic control in adults with type 2 diabetes mellitus

Merck & Co. Inc.:  Merck & Co. Inc. is a popular competitor in the Global Antidiabetics Market. In December 2029, Merck had announced the acquisition of ArQule; the deal was made for USD 2.7 billion. They are a medical device company. The acquisition was made by Merck to strengthen its product portfolio of Oncology medicines

Scope of the Report

By Product

  • Insulin
  • Drugs

By Patient Population

  • Pediatric
  • Adult
  • Geriatric

By Route of Administration

  • Subcutaneous
  • Intravenous infusion
  • Oral
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

Key Reasons to Purchase this Report

  1. It provides a technological development map over time to understand the growth rate of the industry.
  2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
  3. It renders definite analysis for changing competitive dynamics.
  4. It builds a seven-year estimate based on how the market is predicted to grow.

Table of Content

Chapter 1           Overview And Scope

1.1             Market Vision

1.1.1          Market Definition

1.1.2          Market Scope

1.2             Market Segmentation

Chapter 2           Our Research Practice

2.1             Our Research Methodology

2.2             Data Triangulation

2.3             Data Sources

2.4             Assumptions for the study

2.5             Approach Adopted

Chapter 3           Executive Summary

3.1             Market Snapshot

3.2             Regional Snapshot

3.3             Segment Summary

Chapter 4           Covid-19 Impact Analysis

4.1             Overview

4.2             Prevalence analysis

4.3             Key Factor Impact Analysis

Chapter 5           Global Antidiabetics Market Forces

5.1             What’s Driving the Market

5.2             Porter’s Five Forces Analysis

5.2.1          Power of Suppliers

5.2.2          Threats From New Entrants

5.2.3          Power of Buyer

5.2.4          Threat From Substitute Product

5.2.5          Degree of Competition

Chapter 6           Global Antidiabetics Market -Industry Snapshots

6.1             Overview

6.1.1          Global Antidiabetics Market Value, 2019 – 2028, (US$ Bn)

6.2             Market Overview

6.2.1          Drivers Analysis

6.2.2          Restraint/Challenges analysis

6.2.3          Opportunity Analysis

6.3             Supply Chain/Value Chain Analysis

6.4             Market SWOT Analysis

Chapter 7           Global Antidiabetics Market Analysis, by Product

7.1             Overview

7.2             Key Findings for Antidiabetics Market- By Product

7.2.1          Antidiabetics Market- Insulin

7.2.2          Antidiabetics Market- Drugs

Chapter 8           Global Antidiabetics Market Analysis, by Patient Population

8.1             Overview

8.2             Key Findings for Antidiabetics Market- By Patient Population

8.2.1          Antidiabetics Market- Pediatric

8.2.2          Antidiabetics Market- Adult

8.2.3          Antidiabetics Market- Geriatric

Chapter 9           Global Antidiabetics Market Analysis, by Route of Administration

9.1             Overview

9.2             Key Findings for Antidiabetics Market- By Route of Administration

9.2.1          Antidiabetics Market- Subcutaneous

9.2.2          Antidiabetics Market- Intravenous infusion

9.2.3          Antidiabetics Market- Oral

9.2.4          Antidiabetics Market- Others

Chapter 10       Antidiabetics Market Analysis by Region

10.1           Key Findings for Antidiabetics Market- By region

10.2           Overview

10.2.1       Global Antidiabetics Market Analysis, By Product, 2019 – 2028

10.2.2       Global Antidiabetics Market Analysis, By Patient Population, 2019 – 2028

10.2.3       Global Antidiabetics Market Analysis, By Route of Administration, 2019 – 2028

10.3           Antidiabetics Market – North America

10.3.1       Overview

10.3.2       U.S.

10.3.3       Canada

10.3.4       Mexico

10.3.5       North America Market, By Product

10.3.6       North America Market, By Patient Population

10.3.7       North America Market, By Route of Administration

10.4           Antidiabetics Market – Europe

10.4.1       Overview

10.4.2       Germany

10.4.3       United Kingdom

10.4.4       France

10.4.5       Italy

10.4.6       Rest Of Europe

10.4.7       Europe Market, By Product

10.4.8       Europe Market, By Patient Population

10.4.9       Europe market by, Route of Administration

10.5           Antidiabetics Market – Asia Pacific

10.5.1       Overview

10.5.2       China

10.5.3       Japan

10.5.4       India

10.5.5       Rest of APAC

10.5.6       Asia Pacific Market, By Product

10.5.7       Asia Pacific Market, By Patient Population

10.5.8       Asia Pacific Market, By Route of Administration

10.6           Antidiabetics Market – LAMEA

10.6.1       Overview

10.6.2       Middle East & Africa (MEA)

10.6.3       Latin America

10.6.4       Rest Of World

10.6.5       Latin America, Middle East and Africa Market, By Product

10.6.6       Latin America, Middle East and Africa Market, By Patient Population

10.6.7       Latin America, Middle East and Africa Market, By Route of Administration

Chapter 11       Market Competition Analysis

11.1           Market Share/Positioning Analysis

11.1.1       Market Positioning of Key Vendors, 2019

11.1.2       Key Strategies Adopted by the Leading Players

11.1.3       Recent Developments

Chapter 12       Company Profiles- Snapshot

12.1           Astra Zeneca plc

12.1.1       Business Fundamentals

12.1.2       Financial Snapshots

12.1.3       Product Portfolio

12.1.4       Recent Developments

12.2           Eli Lilly & Co.

12.3           Johnson & Johnson

12.4           Mankind Pharma Ltd.

12.5           Merck & Co. Inc.

12.6           Novartis AG

12.7           Chevron Phillips Chemical Company LLC

12.8           Novo Nordisk A/S

12.9           Boehringer Ingelheim GmbH

12.10        Teva Pharmaceutical Industries Ltd.

*More than 10 Companies are profiled in this Research Report*

*Financials would be provided on a best efforts basis for private companies”

Chapter 13       Appendix

 

 

 

Request for Sample

Please fill out the form to receive sample pages of the report